Proof of efficacy for Seladelpar, a selective PPAR-δ agonist, in patients with primary biliary cholangitis non-responsive to ursodeoxycholic acid: results of an international Phase 2 randomised controlled clinical study

Gideon M. Hirschfield, DE Jones, Charles A. McWherter et al.|Journal of Hepatology|2017

Cited by 1